Industry Experts

Mark Messenbaugh is Illumina’s Global Leader for Strategic Market Development & Alliances – Proteomics. He came to Illumina in January 2026 through its acquisition of SomaLogic, where for nearly two decades he helped to pioneer the field of high-plex proteomics. Mark is a passionate advocate for the breakthrough SOMAmer® reagent-based proteomics platform, committed to building the scientific and business partnerships and enabling the innovations that will drive forward its application for biological discovery, drug development and health information.

Mr. Messenbaugh received his Juris Doctor from Columbia Law School and his Bachelors of Arts degree from Harvard University. He was awarded a Fulbright Scholarship for studies in philosophy in Germany and holds an Executive Certificate in Strategy & Innovation from the MIT Sloan School of Management